PubMed HealthSearch

PubMed · 7368982

Marked decrease in serum HDL cholesterol level during acute myocardial infarction.

Abstract

The concentrations of serum total and HDL cholesterol and triglycerides were determined in 57 patients during the course of AMI. In seven days the concentration of serum cholesterol decreased by 24% and that of HDL cholesterol by 31%. The mean HDL/total cholesterol ratio decreased significantly (p less than 0.01) from 0.163 to 0.145. The magnitude of the change in both HDL and total cholesterol showed a positive correlation with infarction size. The concentration of triglycerides decreased in seven days on the average by 31% but there was great individual variation, which was not dependent on infarction size. Four months after infarction both HDL and total cholesterol as well as triglyceride concentrations had returned to the initial levels. There was a significant negative correlation between the concentrations of HDL cholesterol and triglycerides on admission (r = -0.66) and after four months (r = -0.53) but no correlation after seven days. The results indicate that the determination of serum lipids, including HDL cholesterol, in patients with AMI can, and should be performed on admission to hospital and not at the time of discharge, in order to get reliable estimates of these cardiovascular risk factors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Rönnemaa, J Viikari, K Irjala, O Peltola. 1980. Marked decrease in serum HDL cholesterol level during acute myocardial infarction.. https://doi.org/10.1111/j.0954-6820.1980.tb09698.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange.

A number of previous studies have examined the application of liposomes as carriers for the immunosuppressive agent cyclosporine. These studies, however, have generated equivocal results, particularly with regard to the therapeutic properties of such systems. In the present work, we have characterized cyclosporine incorporation into well defined liposomes, large unilamellar vesicles, and have examined the stability of drug association. Contrary to some earlier reports, we show that only modest levels of cyclosporine can be accommodated in the liposomal membrane and that the extent of drug incorporation is greatly reduced as the bilayer cholesterol content is increased. Furthermore, we demonstrate that cyclosporine, despite its hydrophobic character, can rapidly exchange between vesicles. This raises the possibility that, after i.v. administration, drug migration to other blood components might negate the potential benefits arising from liposomal delivery. In a companion paper, therefore (Choice et al., Transplantation, 1995, this issue), we have followed the pharmacokinetics and biodistribution of liposomal cyclosporine in a study that examined the behavior of both the drug and the liposomal carrier.

Cholesterol